Doctor Jeffrey Cummings is world-renowned in the field of Alzheimer’s research and he leads UNLV’s Center for Transformative Neuroscience.

The Western New York Chapter of the Alzheimer’s Association will hold an educational program in Salamanca on the common warning signs of Alzheimer’s disease or dementia and the ...

The Western New York Chapter of the Alzheimer’s Association will offer two free programs in the area next week — one on ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...

BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...